Regulating the activity of class II transactivator by posttranslational modifications: Exploring the possibilities

Molecular and Cellular Biology

Volumn 29, Issue 21, 2009, Pages 5639-5644

  Wu, Xiaoyan ^a   Kong, Xiaocen ^a   Luchsinger, Larry ^b   Smith, Barbara D ^b   Xu, Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSACTIVATOR CLASS 2 PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; DEACETYLATION; GENE CONTROL; GENETIC TRANSCRIPTION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; UBIQUITINATION;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANS-ACTIVATORS;

EID: 70350538958     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00661-09     Document Type: Article

References (41)

1. Abbas, T., D. White, L. Hui, K. Yoshida, D. A. Foster, and J. Bargonetti. 2004. Inhibition of human p53 basal transcription by down-regulation of protein kinase Cdelta. J. Biol. Chem. 279:9970-9977.
2. Asher, G., D. Gatfield, M. Stratmann, H. Reinke, C. Dibner, F. Kreppel, R. Mostoslavsky, F. W. Alt, and U. Schibler. 2008. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell 134:317-328. (Pubitemid 352024391)
3. Buttice, G., J. Miller, L. Wang, and B. D. Smith. 2006. Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ. Res. 98:472-479.
4. Cressman, D. E., K. C. Chin, D. J. Taxman, and J. P. Ting. 1999. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity 10:163-171.
5. Fikrig, E., S. W. Barthold, M. Chen, C. H. Chang, and R. A. Flavell. 1997. Protective antibodies develop, and murine Lyme arthritis regresses, in the absence of MHC class II and CD4+ T cells. J. Immunol. 159:5682-5686. (Pubitemid 127470099)
6. Gourley, T. S., and C. H. Chang. 2001. Cutting edge: the class II transactivator prevents activation-induced cell death by inhibiting Fas ligand gene expression. J. Immunol. 166:2917-2921.
7. Greer, S. F., J. A. Harton, M. W. Linhoff, C. A. Janczak, J. P. Ting, and D. E. Cressman. 2004. Serine residues 286, 288, and 293 within the CIITA: a mechanism for down-regulating CIITA activity through phosphorylation. J. Immunol. 173:376-383.
8. Greer, S. F., E. Zika, B. Conti, X. S. Zhu, and J. P. Ting. 2003. Enhancement of CIITA transcriptional function by ubiquitin. Nat. Immunol. 4:1074-1082.
9. Harton, J. A., E. Zika, and J. P. Ting. 2001. The histone acetyltransferase domains of CREB-binding protein (CBP) and p300/CBP-associated factor are not necessary for cooperativity with the class II transactivator. J. Biol. Chem. 276:38715-38720.
10. Hoffman, M. D., M. J. Sniatynski, and J. Kast. 2008. Current approaches for global post-translational modification discovery and mass spectrometric analysis. Anal. Chim. Acta 627:50-61.
11. Hunter, T. 2007. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol. Cell 28:730-738. (Pubitemid 350217067)
12. Insinga, A., S. Monestiroli, S. Ronzoni, R. Carbone, M. Pearson, G. Pruneri, G. Viale, E. Appella, P. Pelicci, and S. Minucci. 2004. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 23:1144-1154. (Pubitemid 38436878)
13. Iwakuma, T., and G. Lozano. 2007. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 26:2177-2184. (Pubitemid 46536640)
14. Kong, X., M. Fang, P. Li, F. Fang, and Y. Xu. 2009. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. J. Mol. Cell. Cardiol. 46:292-299.
15. Leung, C. H., W. Lam, W. J. Zhuang, N. S. Wong, M. S. Yang, and W. F. Fong. 2001. PKCdelta-dependent deubiquitination and stabilization of Gadd45 in A431 cells overexposed to EGF. Biochem. Biophys. Res. Commun. 285:283-288.
16. Li, G., J. A. Harton, X. Zhu, and J. P.-Y. Ting. 2001. Downregulation of CIITA function by protein kinase A (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines. Mol. Cell. Biol. 21:4626-4635.
17. Meissner, M., T. L. Whiteside, R. Kaufmann, and B. Seliger. 2009. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells. Arch. Dermatol. Res. 301:189-193.
18. Mori-Aoki, A., M. Pietrarelli, M. Nakazato, P. Caturegli, L. D. Kohn, and K. Suzuki. 2000. Class II transactivator suppresses transcription of thyroid-specific genes. Biochem. Biophys. Res. Commun. 278:58-62.
19. Nagarajan, U. M., A. Bushey, and J. M. Boss. 2002. Modulation of gene expression by the MHC class II transactivator. J. Immunol. 169:5078-5088. (Pubitemid 35217177)
20. Nikodemova, M., J. J. Watters, S. J. Jackson, S. K. Yang, and I. D. Duncan. 2007. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. J. Biol. Chem. 282:15208-15216.
21. Nozell, S., Z. Ma, C. Wilson, R. Shah, and E. N. Benveniste. 2004. Class II major histocompatibility complex transactivator (CIITA) inhibits matrix metalloproteinase-9 gene expression. J. Biol. Chem. 279:38577-38589.
22. Raval, A., T. K. Howcroft, J. D. Weissman, S. Kirshner, X. S. Zhu, K. Yokoyama, J. Ting, and D. S. Singer. 2001. Transcriptional coactivator, CIITA, is an acetyltransferase that bypasses a promoter requirement for TAF(II)250. Mol. Cell 7:105-115.
23. Schnappauf, F., S. B. Hake, M. M. Camacho Carvajal, S. Bontron, B. Lisowska-Grospierre, and V. Steimle. 2003. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA. Eur. J. Immunol. 33:2337-2347.
24. Sisk, T. J., T. Gourley, S. Roys, and C. H. Chang. 2000. MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300. J. Immunol. 165:2511-2517.
25. Sisk, T. J., K. Nickerson, R. P. Kwok, and C. H. Chang. 2003. Phosphorylation of class II transactivator regulates its interaction ability and transactivation function. Int. Immunol. 15:1195-1205.
26. Spilianakis, C., J. Papamatheakis, and A. Kretsovali. 2000. Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes. Mol. Cell. Biol. 20:8489-8498.
27. Steimle, V., L. A. Otten, M. Zufferey, and B. Mach. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135-146. (Pubitemid 23306027)
28. Suter, T., U. Malipiero, L. Otten, B. Ludewig, A. Muelethaler-Mottet, B. Mach, W. Reith, and A. Fontana. 2000. Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. Eur. J. Immunol. 30:794-802.
29. Ting, J. P., and K. L. Williams. 2005. The CATERPILLER family: an ancient family of immune/apoptotic proteins. Clin. Immunol. 115:33-37.
30. Tosi, G., N. Jabrane-Ferrat, and B. M. Peterlin. 2002. Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters. EMBO J. 21:5467-5476. (Pubitemid 35231026)
31. Touraine, J. L., and H. Betuel. 1983. The bare lymphocyte syndrome: immunodeficiency resulting from the lack of expression of HLA antigens. Birth Defects Orig. Artic. Ser. 19:83-85.
32. Voong, L. N., A. R. Slater, S. Kratovac, and D. E. Cressman. 2008. Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator. J. Biol. Chem. 283:9031-9039.
33. Wong, A. W., W. J. Brickey, D. J. Taxman, H. W. van Deventer, W. Reed, J. X. Gao, P. Zheng, Y. Liu, P. Li, J. S. Blum, K. P. McKinnon, and J. P. Ting. 2003. CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions. Nat. Immunol. 4:891-898.
34. Xu, Y., J. A. Harton, and B. D. Smith. 2008. CIITA mediates interferon-gamma repression of collagen transcription through phosphorylation-dependent interactions with co-repressor molecules. J. Biol. Chem. 283:1243-1256.
35. Xu, Y., L. Wang, G. Buttice, P. K. Sengupta, and B. D. Smith. 2004. Major histocompatibility class II transactivator (CIITA) mediates repression of collagen (COL1A2) transcription by interferon gamma (IFN-gamma). J. Biol. Chem. 279:41319-41332. (Pubitemid 39328146)
36. Yazawa, T., H. Kamma, M. Fujiwara, M. Matsui, H. Horiguchi, H. Satoh, M. Fujimoto, K. Yokoyama, and T. Ogata. 1999. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J. Pathol. 187:191-199. (Pubitemid 29037048)
37. Ye, Z., and J. P. Ting. 2008. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr. Opin. Immunol. 20:3-9.
38. Yee, C. S., Y. Yao, P. Li, M. J. Klemsz, J. S. Blum, and C. H. Chang. 2004. Cathepsin E: a novel target for regulation by class II transactivator. J. Immunol. 172:5528-5534. (Pubitemid 38542054)
39. Yee, C. S., Y. Yao, Q. Xu, B. McCarthy, D. Sun-Lin, M. Tone, H. Waldmann, and C. H. Chang. 2005. Enhanced production of IL-10 by dendritic cells deficient in CIITA. J. Immunol. 174:1222-1229.
40. 2(I) and other promoters. Mol. Cell. Biol. 21:7078-7088.
41. Zika, E., L. Fauquier, L. Vandel, and J. P. Ting. 2005. Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression. Proc. Natl. Acad. Sci. USA 102:16321-16326.